EMA Authorised: Neuraceq (florbetaben (18F)) — Lantheus Germany GmbH

View source ↗

Summary

EMA authorised Neuraceq (florbetaben [18F]) for use in radionuclide imaging to support assessment of Alzheimer's disease, under Lantheus Germany GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NEURACEQ (Florbetaben F 18)

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging;Alzheimer Disease. MAH: Lantheus Germany GmbH. Decision date: 05/08/2026